Profile data is unavailable for this security.
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
- Revenue in USD (TTM)1.85m
- Net income in USD1.63bn
- Incorporated2024
- Employees166.00
- LocationInhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
- Phone+1 (858) 795-4220
- Fax+1 (302) 636-5454
- Websitehttps://inhibrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eton Pharmaceuticals Inc | 31.38m | -6.69m | 152.69m | 30.00 | -- | 11.30 | -- | 4.87 | -0.2596 | -0.2596 | 1.22 | 0.5229 | 1.00 | 8.82 | 7.89 | 1,046,033.00 | -21.31 | -46.22 | -38.27 | -58.20 | 59.48 | 72.16 | -21.31 | -76.86 | 1.28 | -- | 0.2571 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Biostem Technologies Inc | 131.44m | 7.87m | 158.96m | 67.00 | 29.17 | 8.78 | 19.66 | 1.21 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
| Lifecore Biomedical Inc | 128.26m | 9.33m | 160.67m | 524.00 | 35.09 | 14.05 | 8.83 | 1.25 | 0.1482 | 0.2318 | 3.83 | 1.76 | 0.5055 | 2.14 | 4.26 | 244,774.80 | 3.68 | -5.91 | 4.35 | -8.33 | 32.63 | 31.01 | 7.27 | -19.16 | 1.06 | 0.2373 | 0.6923 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| ASP Isotopes Inc | 2.30m | -27.05m | 177.39m | 76.00 | -- | 12.59 | -- | 77.27 | -0.628 | -0.628 | 0.0549 | 0.2112 | 0.068 | -- | -- | 30,206.32 | -71.81 | -- | -89.44 | -- | 36.54 | -- | -1,055.85 | -- | -- | -8.11 | 0.6748 | -- | -- | -- | -229.34 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.74m | 177.66m | 1.00 | -- | 113.33 | -- | -- | -0.6855 | -0.6855 | 0.00 | 0.0529 | 0.00 | -- | -- | 0.00 | -467.16 | -- | -686.91 | -- | -- | -- | -- | -- | -- | -0.9299 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.22m | 186.26m | 3.00 | -- | 31.52 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 189.52m | 100.00 | -- | 9.13 | -- | 9.41 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Scilex Holding Co | 50.83m | -171.53m | 193.71m | 113.00 | -- | -- | -- | 3.81 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 196.08m | 384.00 | -- | 0.7503 | -- | 0.6563 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 204.21m | 5.50k | 3.47 | 5.18 | 2.93 | 0.4932 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 239.82m | 147.00 | -- | -- | -- | 1.84 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Inhibrx Biosciences Inc | 1.85m | 1.63bn | 245.95m | 166.00 | 0.1402 | 1.12 | 0.1502 | 132.73 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Scpharmaceuticals Inc | 24.05m | -60.64m | 271.66m | 135.00 | -- | 21.22 | -- | 11.30 | -1.56 | -1.56 | 0.6187 | 0.256 | 0.2678 | 0.6563 | 6.23 | 178,133.30 | -67.52 | -38.23 | -75.77 | -42.31 | 71.15 | -- | -252.18 | -1,360.16 | 3.66 | -13.66 | 0.8121 | -- | -- | -- | -48.79 | -- | -- | -- |
| Sanara Medtech Inc | 72.41m | -6.57m | 272.12m | 107.00 | -- | 6.52 | -- | 3.76 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Precigen Inc | 4.39m | -135.38m | 296.96m | 202.00 | -- | 6.09 | -- | 67.66 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Data as of Sep 19 2024. Currency figures normalised to Inhibrx Biosciences Inc's reporting currency: US Dollar USD
40.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 30 Jun 2024 | 1.79m | 12.35% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 1.06m | 7.35% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 624.04k | 4.31% |
| Walleye Capital LLCas of 30 Jun 2024 | 475.00k | 3.28% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 463.91k | 3.21% |
| Slotnik Capital LLCas of 30 Jun 2024 | 341.61k | 2.36% |
| Alpine Associates Management, Inc.as of 30 Jun 2024 | 305.97k | 2.11% |
| Millennium Management LLCas of 30 Jun 2024 | 303.20k | 2.09% |
| TIG Advisors LLCas of 30 Jun 2024 | 243.65k | 1.68% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 235.56k | 1.63% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
